Clearside Biomedical Inc

Clearside Biomedical — Investor Presentation (March 2018)

39 slides from Clearside Biomedical's investor presentation, Mar 27, 2018

  1. Slide 1: Corporate Presentation | March 2018

    Corporate Presentation | March 2018 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: A World Without Blindness

    | Developing advanced clinical and preclinical product candidates, using a proprietary suprachoroidal treatment approach: We see a world without blindness; relentlessly pursuing transformative, elegant, precise solutions to restore and preserve vision A World Without Blindness Unmet or underserved b

  4. Slide 4: Privileged Organ Requiring Local Therapy

    Privileged Organ Requiring Local Therapy Limitations of Current Approaches to Local Administration Include: Corticosteroids reach unintended tissues, causing cataracts and glaucoma Multi-kinase inhibitors and gene therapies require precise placement at diseased tissue Certain drugs like complement i

  5. Slide 5: Exclusive and Proprietary Access to the Back of the Eye Through the Suprachoroidal Space

    Exclusive and Proprietary Access to the Back of the Eye Through the Suprachoroidal Space (“SCS”) VS Intravitreal & Periocular Suprachoroidal | Fluid flows instantaneously and posteriorly Designed consistent suprachoroidal injection procedure Fluid with drug is absorbed into the choroid, RPE and reti

  6. Slide 6: Designed to Improve Ocular Distribution of Triamcinolone Acetonide

    Concentration (ng/g) Time, days SUPRACHOROIDAL CLS-TA The anterior segment is relatively spared following suprachoroidal dosing when compared to intravitreal dosing Designed to Improve Ocular Distribution of Triamcinolone Acetonide (TA) | Over 10X the amount of TA remaining in the choroid and RPE fo

  7. Slide 7: Focused Pipeline of SCS Treatments For Multiple Blinding Eye Diseases

    INDICATION STUDY DRUG CURRENT STATUS Uveitis (macular edema associated with non-infectious uveitis) Suprachoroidal CLS-TA (corticosteroid triamcinolone acetonide) RVO (retinal vein occlusion) Suprachoroidal CLS-TA with anti-VEGF (Intravitreal Eylea®) DME (diabetic macular edema) Suprachoroidal CLS-T

  8. Slide 8: Major Near-Term Anticipated Milestones

    2018 2019 Uveitis RVO DME NDA review Phase 3 (SAPPHIRE) P3 Data (PEACHTREE) Topline P2 Data (TYBEE) Phase 3 (TOPAZ) NDA Submission Publications | Major Near-Term Anticipated Milestones Provide Multiple Potential Value-Inflection Points Topline P3 Data

  9. Slide 9: Uveitis: One of the World's Leading Causes of Blindness

    UVEITIS One of the World’s Leading Causes of Blindness |

  10. Slide 10: Current Treatment Paradigm

    Current Treatment Paradigm Note: TA = triamcinolone acetonide. Corticosteroids = most common treatment for all uveitis complications, including macular edema Periocular (Sub-tenon) 20 mg TA Sustained release dexamethasone implant (Ozurdex®) Intravitreal 4 mg TA Topical steroid for anterior uveitis 3

  11. Slide 11: The Opportunity in Treating Macular Edema with Uveitis

    The Opportunity | In Treating Macular Edema with Uveitis Primary Need An approved therapy that targets vision impairment due to the underlying macular edema associated with all non-infectious uveitis The Problem Inflammation creates sight threatening macular edema No approved treatment for macular e

  12. Slide 12: PEACHTREE Design for Pivotal Phase 3 Clinical Trial

    PEACHTREE Design for Pivotal Phase 3 Clinical Trial 3:2 randomization of suprachoroidal CLS-TA vs. sham injection; 160 patients total Primary endpoint at 6 months; superiority of best corrected visual acuity outcome from treatment SHAM Week-2 Day 0 Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24

  13. Slide 13: Primary Endpoint ETDRS BCVA

    46.9% (n=45) 15.6% (n=10) % patients gaining ≥15 ETDRS letters in BCVA from baseline Primary Endpoint ETDRS BCVA Proportion of patients in each arm gaining ≥ 15 ETDRS letters in BCVA from baseline at Week 24 p<0.001 |

  14. Slide 14: Secondary Endpoint Mean Change from Baseline in CRT at Week 24

    Secondary Endpoint Mean Change from Baseline in CRT at Week 24 in microns Mean change from baseline at week 24 in central retinal thickness (microns) 479.8 µm: active arm; 518.0 µm: control arm p<0.001 | Baseline retinal thickness (microns) N=96 N=64 ITT

  15. Slide 15: Secondary Endpoint Mean Change in BCVA in ETDRS Letters by Visit

    Table 14.2.3.3; Source: Listing 16.2.6.1 Summary of Best Corrected Visual Acuity by Visit, Study Eye (LOCF Method); ITT population Secondary Endpoint Mean Change in BCVA in ETDRS Letters by Visit | Mean change from baseline in BCVA in ETDRS letters read by visit Baseline ETDRS letters read 54.7: act

  16. Slide 16: AE: Cataracts in CLS-TA and Sham Arms

    AE: Cataracts in CLS-TA and Sham Arms Percentage of cataract AEs Mar-2018 | NIU program | P3, PEACHTREE, trial | Topline data | % Cataract AEs in Each Arm There were no treatments (i.e. surgeries) because of cataract AEs

  17. Slide 17: PEACHTREE Safety Summary

    PEACHTREE Safety Summary 97% of the randomized patients completed the trial No serious adverse events related to treatment Through 24 weeks, steroid-related elevated IOP adverse events were reported for 11.5% of patients in the CLS-TA treatment group, compared to no patients in the sham group |

  18. Slide 18: Next Steps

    Next Steps Based on feedback from end-of-Phase 2 meeting with the FDA, we believe PEACHTREE will be the only Phase 3 clinical trial required to support the filing of a New Drug Application (NDA) Detailed results from PEACHTREE will be presented at an upcoming medical conference Positioning the compa

  19. Slide 19: RVO: New Approach with CLS-TA + anti-VEGF

    RVO New Approach with CLS-TA + anti-VEGF |

  20. Slide 20: Current Treatment Paradigm

    | Current Treatment Paradigm Eylea, Lucentis, and off-label Avastin® Sustained release dexamethasone implant (Ozurdex®) Intravitreal Triamcinolone Acetonide 16.4 M patients Global RVO patients 2nd Line treatment 2.2 M patients US RVO patients 1 2 3 1st Line treatment

  21. Slide 21: The Opportunity in Treating RVO

    The Opportunity In Treating RVO | Primary Needs More rapid and fuller resolution of macular edema to allow patients to recover as much vision as soon as possible The Problem Compared to uveitis and DME, macular edema following RVO is more severe, as is the attendant vision loss / potential vision ga

  22. Slide 22: 60% Fewer Additional Intravitreal Eylea Injections

    Intent-to-treat (ITT) population: N = 46 (23:23) Additional Intravitreal Eylea Injections p=0.013 Control arm: Intravitreal Eylea Active arm: Intravitreal Eylea + Suprachoroidal CLS-TA | Number of Additional Injections 60% fewer additional intravitreal Eylea injections in the suprachoroidal CLS-TA +

  23. Slide 23: Number of Patients Requiring Additional Treatment Reduced

    1 Based on post-hoc analysis Number of patients who received additional Intravitreal Eylea p=0.003 Intent-to-treat (ITT) population: N = 46 (23:23) 1 Control arm: Intravitreal Eylea Active arm: Intravitreal Eylea + Suprachoroidal CLS-TA | Number of Patients Requiring Additional Treatment Reduced 69%

  24. Slide 24: Improved Visual Acuity

    Aflibercept Arm; N=23 Combination Arm; N=23 Baseline: 49 ETDRS letters read in each arm * Note: Bars are standard error of the mean; * only month 2 showed p<0.05 Improved Visual Acuity Suprachoroidal CLS-TA + intravitreal Eylea resulted in improved visual acuity at months 1, 2, 3 vs. intravitreal Ey

  25. Slide 25: Retinal Thickness Reductions

    Baseline 728 µm and 731 µm in the Aflibercept and Combination arms Aflibercept Arm; N=23 Combination Arm; N=23 Month 2 Month 1 Month 3 310 µm | Retinal Thickness Reductions Suprachoroidal CLS-TA + intravitreal Eylea resulted in sustained retinal thickness reductions at months 1, 2, 3 vs. intravitrea

  26. Slide 26: Post-TANZANITE Evaluation

    Combination (n=20) 3 (15%) including Month 3 patients re-treated Monotherapy (n=11) 6 (55%) re-treated Eylea arm: 17% (n=4/23) | Post-TANZANITE Evaluation 74% of patients who received combination therapy did not receive additional treatment through a minimum 9 months Combination arm: 74% (n=17/23)

  27. Slide 27: Design for First Phase 3 RVO Clinical Trial (SAPPHIRE)

    | SAPPHIRE Control arm Intravitreal Eylea; Q4Wk Combination arm Suprachoroidal CLS-TA + Intravitreal Eylea; Q12Wk Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week ww Week xx Week yy Week zz 2 Month primary efficacy endpoint Submit with 6 months data Continue to follow subjects out to 1 year

  28. Slide 28: TOPAZ Phase 3 RVO Trial Design

    If the primary endpoint is met in SAPPHIRE and TOPAZ, where CLS-TA has been used in combination with one of three anti-VEGF agents - Eylea, Lucentis and Avastin - the objective will be to seek a class label in the US where suprachoroidal CLS-TA can be used with any intravitreal anti-VEGF agent for t

  29. Slide 29: DME: Suprachoroidal CLS-TA Alone or in Combination with an Anti-VEGF Agent

    DME Suprachoroidal CLS-TA Alone or in Combination with an Anti-VEGF Agent |

  30. Slide 30: Steroids Given Frequently to Treat DME

    | Steroids Given Frequently to Treat DME CSME = Clinically significantly macular edema DME = diabetic macular edema National Center for Chronic Disease Preventions and Health Promotion: Division of Diabetes Translation. National Diabetes Statistical Report, 2014 International Diabetes Federation. ID

  31. Slide 31: The Opportunity in Treating DME

    Primary Need Rapid reduction of edema to maximize vision gain early in course of treatment The Opportunity In Treating DME | The Problem Protocol T demonstrated that greater visual gains in the first three months result in improved long-term outcome in DME patients DME is response to anti-VEGF injec

  32. Slide 32: Background: Corticosteroid and Anti-VEGF Therapy

    | Background Corticosteroid Therapy Iluvien and Ozurdex are approved for treatment of patients with DME Results appear to be better in subjects with pseudo-phakic eyes vs. phakic eyes Adverse events, especially in phakic eyes, often appear to compromise visual gains seen within the first few months

  33. Slide 33: HULK Data Presented at AAO 2017

    HULK Data Presented at AAO 2017 First trial with CLS-TA in DME patients to obtain exploratory information Encouraging preliminary safety and efficacy data from both Tx naïve and previous Tx arms support continued clinical development Tx Naïve Arm Four (4) of 10 (40%) patients required NO additional

  34. Slide 34: TYBEE Design for Phase 2 DME Clinical Trial

    | TYBEE Design for Phase 2 DME Clinical Trial CLS-TA Eylea Any additional treatment based on PRN criteria will be intravitreal aflibercept Evaluate at 6 months Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Enrollment Day 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Arm 2: Intravitreal Eylea

  35. Slide 35: A World Without Blindness: In Summary

    A WORLD WITHOUT BLINDNESS In Summary |

  36. Slide 36: Patent portfolio

    | Patent No. Significance Expiration U.S. 7,918,814 Provides exclusivity for the administration of any drug to the eye by inserting a microinjector into the sclera or corneal stroma of a patient’s eye, and infusing the drug into the sclera or cornea 2029 U.S. 8,197,435 Provides exclusivity for admin

  37. Slide 37: Leadership: Accomplished Team with Deep Ophthalmic Experience

    | Leadership Accomplished Team with Deep Ophthalmic Experience Experience Years DANIEL WHITE President, CEO and Director GSK, Stiefel, CIBA Vision, Alimera 25 CHARLES DEIGNAN Chief Financial Officer AtheroGenics, AAIPharma, Schering-Plough 27 GLENN NORONHA, Ph.D. Chief Scientific Officer Alcon, Suca

  38. Slide 38: Major Near-Term Anticipated Milestones

    2018 2019 Uveitis RVO DME NDA review Phase 3 (SAPPHIRE) P3 Data (PEACHTREE) Topline P2 Data (TYBEE) Phase 3 (TOPAZ) NDA Submission Publications | Major Near-Term Anticipated Milestones Provide Multiple Potential Value-Inflection Points Topline P3 Data

  39. Slide 39: Thank You!

    THANK YOU! We see a world without blindness; relentlessly pursuing transformative, elegant, precise solutions to restore and preserve vision.

Clearside Biomedical — Investor Presentation (March 2018) on 6ix